Active, not recruitingPhase 3NCT05206773
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
Studying Fabry disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Principal Investigator
- Clinical Sciences & OperationsSanofi
- Intervention
- Venglustat (GZ402671)(drug)
- Enrollment
- 122 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2022 – 2025
Study locations (20)
- Nephrology Clinic at Kirklin Clinic of UAB Hospital_Investigational Site Number: 8400011, Birmingham, Alabama, United States
- UCLA Medical Center_Investigational Site Number: 8400006, Los Angeles, California, United States
- University of California Irvine Medical Center- Site Number : 8400019, Orange, California, United States
- Advent Health Orlando_Investigational Site Number: 8400008, Orlando, Florida, United States
- Emory Genetics- Site Number : 8400010, Atlanta, Georgia, United States
- Westchester Medical Center Healthcare Corporation- Site Number : 8400001, Hawthorne, New York, United States
- Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400013, Cincinnati, Ohio, United States
- Cleveland Clinic Site Number : 8400016, Cleveland, Ohio, United States
- Children's Hospital Of Pittsburgh- Site Number : 8400009, Pittsburgh, Pennsylvania, United States
- Renal Disease Research Institute, An affiliate of: Dallas Nephrology Associates_Investigational Site Number: 8400012, Dallas, Texas, United States
- University Of Utah Health Sciences Center- Site Number : 8400005, Salt Lake City, Utah, United States
- Lysosomal and Rare Disorders Research and Treatment Center_Investigational Site Number: 8400004, Fairfax, Virginia, United States
- Fundacion Cori para la Investigación y Prevención del Cancer_Investigational Site Number: 0320002, La Rioja, Argentina
- Instituto de Investigaciones Clínicas Quilmes (IICQ) SRL_Investigational Site Number: 0320003, Quilmes, Argentina
- Investigational Site Number : 0360001, Parkville, Victoria, Australia
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05206773 on ClinicalTrials.govOther trials for Fabry disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06906367A Study of Patients With Fabry Disease (US Specific)Amicus Therapeutics
- RECRUITINGPHASE3NCT06904261A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsAmicus Therapeutics
- RECRUITINGNCT07235709Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR StudyYonsei University
- RECRUITINGNANCT07187440A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseTakeda
- ENROLLING BY INVITATIONNANCT07495410Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FITGeneral University Hospital, Prague
- RECRUITINGPHASE2, PHASE3NCT06328608A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseaseChiesi Farmaceutici S.p.A.
- RECRUITINGNANCT07382128Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy PhenotypesIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT06941025Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingChiesi Farmaceutici S.p.A.